Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB).

Full DD Report for XTLB

You must become a subscriber to view this report.


Recent News from (NASDAQ: XTLB)

XTL Biopharmaceuticals reports 1H results
XTL Biopharmaceuticals (NASDAQ: XTLB ): 1H EPS of -$0.002 More news on: XTL Biopharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: July, 24 2018 09:17
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update
RAMAT GAN , Israel , July 24, 2018 /PRNewswire/ --  XTL Biopharmaceuticals Ltd.   (NASDAQ: XTLB) (TASE: XTLB.TA)   ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results ...
Source: PR Newswire
Date: July, 24 2018 09:09
Midday Gainers / Losers (06/19/2018)
Gainers: ASTC +205% . GEVO +82% . SLDB +59% . SRPT +42% . NEPT +40% . CLBS +36% . FMI +28% . SPRO +28% . SRRK +22% . NURO +22% . More news on: Astrotech Corporation, Gevo, Inc., Solid Biosciences, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: June, 19 2018 12:45
XTL Biopharmaceuticals reports Q1 results
XTL Biopharmaceuticals (NASDAQ: XTLB ): Q1 EPS of $0.002 More news on: XTL Biopharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 29 2018 17:41
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update
RAMAT GAN , Israel , May 29, 2018 /PRNewswire/ --  XTL Biopharmaceuticals Ltd.   (NASDAQ: XTLB) (TASE: XTLB.TA)   ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for th...
Source: PR Newswire
Date: May, 29 2018 17:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-072.202.242.242.201,600
2018-12-062.182.192.302.181,952
2018-12-052.302.292.30962.298,150
2018-12-042.302.292.30962.298,150
2018-12-032.372.362.442.2519,008

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-069001,75051.4286Short
2018-12-033002,79910.7181Cover
2018-11-274001,73023.1214Cover
2018-11-264,6546,67969.6811Short
2018-11-2110025040.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XTLB.


About XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)

Logo for XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the development, in licensing, acquisition, and commercialization of proprietary products and late stage pharmaceutical product candidates for the treatment of unmet medical needs.

 

Contact Information

 

 

Current Management

  • David Grossman / CEO
  • Ronen Twito / CFO

Current Share Structure

  • Market Cap: $1,007,843,366 - 05/18/2018
  • Issue and Outstanding: 514,205,799 - 12/31/2017

 


Recent Filings from (NASDAQ: XTLB)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 22 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 10 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 15 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 07 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Correspondence from the Filer to the SEC
Filing Type: CORRESPFiling Source: edgar
Filing Date: March, 02 2018
This filing is a pre-effective amendment to an F-1 filing
Filing Type: F-1/AFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: XTLB)

Daily Technical Chart for (NASDAQ: XTLB)


Stay tuned for daily updates and more on (NASDAQ: XTLB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: XTLB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XTLB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of XTLB and does not buy, sell, or trade any shares of XTLB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/